Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

with millions of people affected by this debilitating condition," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "With the designation of RDEA594 as our clinical candidate for the treatment of gout, we now expect to have five novel candidates in clinical testing during the second half of 2008, positioning us with the potential to have a broad-based, late-stage pipeline in 2009. This finding also allows us to focus our future development efforts with RDEA806 on the treatment of HIV."

The Company plans to initiate a Phase 1 clinical study of RDEA594 in the second half of this year. As previously announced, the Company also plans to conduct a Phase 2 proof-of-concept clinical study in patients with gout, to confirm RDEA594's activity in the target population using its prodrug, RDEA806. This study is on track to be initiated in the second quarter of this year.

The EULAR presentation details are as follows:

Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST

Title: Safety and Uric Acid Lowering Effect in Humans Following Multiple

Doses of RDEA806, A Novel Prodrug for the Potential Treatment of

Hyperuricemia

Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0356)

Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST

Title: Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans

Following Multiple Doses of its Prodrug, RDEA806

Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0357)

About Gout

An estimated 3-5 million people in the United States suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connecti
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has ... (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava ... by 2016. The North America ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... Grifols, a global healthcare company and biopharmaceutical manufacturer based ... an Expert Advisory Council in Transfusion Medicine drawing on ... across the globe.  The role of the Expert Advisory ... Grifols, own transfusion medicine research and development activities. ...
... CareFusion Corporation (NYSE: CFN ... of Carlos M. Nunez, M.D. as its chief medical officer ... and hospitalist as well as an experienced health care technology ... the areas of clinical effectiveness, information technology, public policy and ...
Cached Medicine Technology:Grifols Establishes Expert Advisory Council in Transfusion Medicine 2Grifols Establishes Expert Advisory Council in Transfusion Medicine 3CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... all types of dementia, including Alzheimer,s disease, finds a new ... The study of more than 1,000 people in Japan found ... to 20 percent of people with normal blood sugar levels. ...
... with low sunlight are up to 3 times more ... should take high levels of Vitamin D supplements, according to ... "This study shows that the current one-size fits ... don,t work," said Adam Murphy, M.D., a clinical instructor in ...
... improvements in treating heart attack patients needing emergency artery-opening ... hospitals that can perform the procedure, according to a ... Association . Fast response is critical for ST-segment ... is caused by a complete blockage of blood supply ...
... (MEMPHIS, Tenn. September 19, 2011) The largest study ever ... the tumors carried extra copies of specific genes linked to ... Research Hospital investigators. The findings identify possible new ... as diffuse intrinsic pontine glioma (DIPG). Current survival rates for ...
... of boredom or fatigue, yawning might also be a ... by Andrew Gallup, a postdoctoral research associate in Princeton ... first involving humans to show that yawning frequency varies ... to yawn when the heat outdoors exceeds body temperature. ...
... MONDAY, Sept. 19 (HealthDay News) -- Obese 8- and ... their normal-weight peers, a new study finds. In the ... height and weight, at ages 4 and 5 and then ... questionnaires that assessed children,s mental health and health-related quality of ...
Cached Medicine News:Health News:More Evidence Links Diabetes, Dementia 2Health News:More Evidence Links Diabetes, Dementia 3Health News:One size doesn't fit all for vitamin D and men 2Health News:Emergency treatment for heart attack improving but delays still occur 2Health News:Emergency treatment for heart attack improving but delays still occur 3Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:More than a sign of sleepiness, yawning may cool the brain 2Health News:More than a sign of sleepiness, yawning may cool the brain 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: